drugset / Trial / NCT04948333
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).
Timeline
- Start
- 2021-10-13
- Primary completion
- 2024-03-12
- Completion
- 2026-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asciminib | Unknown | 40 mg | Oral |
| Subject | Asciminib | Unknown | 80 mg | Oral |
| Subject | Asciminib | Unknown | 200 mg | Oral |